Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
First Claim
Patent Images
1. A chimeric antigen receptor (CAR) comprising:
- (a) an antigen binding domain of a KDR-1121 or DC101 antibody wherein the antigen binding domain comprises an amino acid sequence comprising SEQ ID NO;
1 or 2;
(b) an amino acid sequence comprising SEQ ID NO;
3, 4, or 7; and
(c) an amino acid sequence comprising SEQ ID NO;
5, 6, 8, or 9.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
135 Citations
12 Claims
-
1. A chimeric antigen receptor (CAR) comprising:
-
(a) an antigen binding domain of a KDR-1121 or DC101 antibody wherein the antigen binding domain comprises an amino acid sequence comprising SEQ ID NO;
1 or 2;(b) an amino acid sequence comprising SEQ ID NO;
3, 4, or 7; and(c) an amino acid sequence comprising SEQ ID NO;
5, 6, 8, or 9. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
Specification